Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Menopause01:28

Menopause

138
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
138
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

296
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
296
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

49
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
49
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194
Depression: Overview01:18

Depression: Overview

216
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
216

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease: Interdisciplinary Considerations and Management.

Neurogastroenterology and motility·2026
Same author

Editorial: Menopause and mental health.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same author

The brain in transition: Perimenopause through a translational lens.

Neuroscience and biobehavioral reviews·2026
Same author

Statistical analysis plan for Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial; a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery.

Trials·2026
Same author

Functional neural changes linked to depression during the menopause transition and the effects of hormone therapy: A narrative review.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

The Impact of Estradiol Dynamics During the Menopause Transition on Depression Risk: A Narrative Review of Estradiol's Neurobiological Mechanisms.

Biological psychiatry·2026

Related Experiment Video

Updated: Jun 6, 2025

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
09:07

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats

Published on: February 23, 2015

13.3K

Estradiol modulates resting-state connectivity in perimenopausal depression.

Megan Hynd1, Kathryn Gibson2, Melissa Walsh2

  • 1Department of Psychology & Neuroscience, University of North Carolina, Chapel Hill, NC, United States of America.

Journal of Affective Disorders
|November 24, 2024
PubMed
Summary

Estradiol (E2) treatment shows promise for perimenopausal depression by altering brain connectivity. This study found E2 shifts resting-state functional connectivity (rsFC) in women with perimenopausal-onset MDD, linking these changes to symptom improvement.

Keywords:
AmygdalaCaudate-nucleusEstradiolMenopausePerimenopause-onset major depressive disorderPutamenResting-state functional connectivity

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.1K
Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression
08:42

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

10.4K

Related Experiment Videos

Last Updated: Jun 6, 2025

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
09:07

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats

Published on: February 23, 2015

13.3K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.1K
Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression
08:42

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

10.4K

Area of Science:

  • Neuroscience
  • Endocrinology
  • Psychiatry

Background:

  • The perimenopausal transition increases the risk of affective dysregulation and major depressive disorder (MDD).
  • Estradiol (E2) replacement therapy is a potential treatment for perimenopausal-onset MDD (PO-MDD), but its neural mechanisms are unclear.
  • Previous research suggests E2 influences mood by modulating cortico-subcortical brain connectivity.

Purpose of the Study:

  • To investigate the effects of transdermal E2 on resting-state functional connectivity (rsFC) in perimenopausal women.
  • To compare rsFC patterns in women with and without PO-MDD before and after E2 treatment.
  • To explore the relationship between E2-induced rsFC changes and mood symptom trajectories.

Main Methods:

  • Pharmaco-fMRI study involving 16 women with PO-MDD and 18 controls.
  • rsFC analysis was conducted before and after three weeks of transdermal E2 administration.
  • Seed regions were selected within reward and emotion processing networks (amygdala, caudate nucleus, putamen).

Main Results:

  • Pre-treatment: PO-MDD group showed altered amygdala connectivity compared to controls.
  • Post-treatment: E2 administration induced significant changes in rsFC in the PO-MDD group, including altered connectivity in the caudate nucleus, putamen, and amygdala.
  • Connectivity changes predicted symptom improvements in anhedonia, depressive mood, somatic, and vasomotor domains.

Conclusions:

  • Distinct rsFC patterns characterize PO-MDD, and these patterns shift with E2 treatment.
  • E2 treatment may alleviate PO-MDD symptoms by modulating cortico-subcortical functional connectivity.
  • These findings provide insights into the neural mechanisms underlying E2's mood-modulating effects in perimenopausal depression.